Objective: An increase in the use of selective serotonin reuptake inhibitors (SSRIs) and/or serotoninnorepinephrine reuptake inhibitors (SNRIs) to relieve menopausal hot flashes (HFs) has been observed recently. However, response to them has been heterogeneous. We hypothesized that this heterogeneity might be partially attributed to genetic variations in genes encoding the serotonin and/or norepinephrine transporters (SLC6A4 and SLC6A2). As a first step in testing the role of genetics in response to SSRIs/SNRIs, we examined the association between HFs and genetic variants within these two genes.
H ot flashes (HFs) are the most common symptoms of menopause. They are of concern because they significantly reduce the quality of life of millions of women and are women's primary reason for seeking medical help during the menopausal transition. Furthermore, HFs are of concern because they might also be associated with other serious conditions, including cardiovascular diseases and osteoporosis. 1<3 HFs are caused by ovarian senescence and declining levels or lack of estrogens and progesterone. In addition, the irregular release of these hormones from the ovaries also contributes to the generation of HFs. In addition to estrogens and progesterone, environmental and genetic factors also play a role in the etiology of HFs. Confirmed environmental risk factors for HFs include smoking; late menopause stages; low levels of estrogen, inhibin A, and inhibin B; high levels of follicle-stimulating hormone; African-American (AA) race; and high body mass index (BMI). 4, 5 There is also inconsistent or weak evidence for other risk factors such as alcohol use, physical inactivity, mood disorders such as depression and anxiety, life events such as childhood abuse and mental workload, and past hormone therapy (HT). 4, 5 Because hormone levels play a major role in the etiology of HFs, several investigators hypothesized that genetic determinants of hormone levels might be linked to HFs and thus tested whether genetic polymorphisms in genes encoding estrogen receptors and the estrogen biosynthesis and metabolic pathway (CYP450) were associated with HFs. Indeed, it has been demonstrated that Chinese women who were carriers of the CYP1A1_rs2606345 variant reported diminished vasomotor symptoms compared with noncarriers. 6 An association between CYP1B1 variants in AA women and symptom reporting has been described by several groups. 6<8 In addition to providing evidence that smoking and genetic variation in sex steroid metabolism impact menopausal endpoints separately, 9<11 a recent study has shown interactions between variants in sex steroidYmetabolizing genes (CYP450 and COMT [catechol O-methyl-transferase]) and smoking behavior on the risk of menopausal symptoms. 12 Estrogen receptor single nucleotide polymorphisms (SNPs) are also associated with the frequency of tamoxifen-induced HFs, 13 suggesting that estrogen receptor genotype may be used to predict individuals who may experience HFs during tamoxifen treatment. SNPs of the CYP19 gene may predict the risk of breast cancer in healthy women, 14, 15 are associated with lower estrogen levels and subsequent HFs and arthralgia, 16 and may change the response of breast cancer progression to letrosole and tamoxifen treatment. 17, 18 Before 2002, estrogen therapy (ET) or combined estrogenprogestin therapy (HT) was widely used among premenopausal, perimenopausal, and postmenopausal women to alleviate HFs and other menopausal symptoms such as depression, sleeplessness, and diminished sexual desire. However, data from the Women's Health Initiative, published in 2002, 19 raised some serious concerns about the use of HT, including potential elevation of the incidence of breast cancer, deep venous thrombosis, and stroke. Although ET had fewer adverse effects than HT, it still was reported to increase the incidence of cerebrovascular stroke. Even though reanalysis of the data by age group clearly showed that adverse effects are minimal and beneficial effects are dominant when ET or HT is taken within 10 years of the cessation of the menstrual cycle, 20 a large number of women stopped taking ET or HT. As a consequence, many women turned to other treatment options to relieve their menopausal symptoms. Among these options, the use of selective serotonin reuptake inhibitors (SSRIs) and/or serotoninnorepinephrine reuptake inhibitors (SNRIs) became popular. However, it has become clear that SSRIs/SNRIs are less efficient than ET or HT and that response to them has been heterogeneous. 21<23 This heterogeneous response might be attributed to single SNPs on the serotonin transporter gene or the norepinephrine transporter gene. No studies have examined whether genetic polymorphisms in SSRIs/SNRIs were associated with HFs, although a large number of publications reported an association with psychiatric disorders. 24 Such an association with HFs, however, needs to be explored to enable clinicians to prescribe SSRIs/SNRIs only to those who lack such polymorphisms and, consequently, to determine who will most probably benefit from such therapy.
As a first step in testing genetic variants for drug response, we first examined the association between HFs and genetic variants within a norepinephrine transporter gene (SLC6A2) and a serotonin transporter gene (SLC6A4) in both European-American (EA) and AA premenopausal and perimenopausal women.
METHODS

Study population
Participants were recruited for a cross-sectional study of risk factors for menopausal HFs in midlife women. Detailed methods of participant recruitment are described elsewhere. 8, 25 Briefly, between 2000 and 2004, generally healthy women who were residing in Baltimore City and surrounding counties were sent recruitment letters via mail. Potential participants had to meet the following eligibility criteria: aged 45 to 54 years, not taking HT, not pregnant, and without a history of cancer. Furthermore, because the study was designed to examine the health of women undergoing the menopausal transition, women were eligible only if they reported having had at least three menstrual periods in the last 12 months. Therefore, all women in the study were either premenopausal or perimenopausal. Premenopausal women were those who experienced their last menstrual period within the past 3 months and reported 11 or more periods within the past year. Perimenopausal women were those who experienced (1) their last menstrual period within the past year, but not within the past 3 months or (2) their last menstrual period within the past 3 months and experienced 10 or fewer periods within the past year. Eligible women were scheduled to come to the clinic during morning hours and were instructed to fast overnight before the visit. During the clinic visit, each participant had her weight and height measured, and a blood sample was drawn for genetic analyses. The participants also completed the detailed study survey, which included questions regarding demographics; medical, family, and reproductive history; past exogenous hormone use; menopausal symptoms; and lifestyle habits (eg, smoking and diet). All participants in this study gave a written informed consent form according to the procedures approved by the University of Illinois, University of Maryland, and Johns Hopkins University Institutional Review Boards.
Age and race/ethnicity were self-reported. BMI was calculated based on the height and weight measurements of the participant at the clinic visit and was categorized as normal (e24.9 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), or obese (Q30.0 kg/m 2 ). Smoking status at the time of enrollment (current, former, never) was determined using the questions, BHave you ever smoked cigarettes?[ and BDo you still smoke cigarettes?[ A woman's history of ever experiencing midlife HFs was determined using the question, BHave you ever experienced hot flashes?[ Women experiencing HFs were further queried regarding HF severity (mild, moderate, or severe), frequency (daily, weekly, or monthly), and duration (number of months/years). HF outcomes examined in the analyses were as follows: ever experienced HFs, moderate or severe HFs, daily HFs, and HFs experienced for 1 year or longer (long duration). For all HF outcomes, the comparison group never experienced HFs.
SNP selection, genotyping, and analysis
Thirty-six haplotype-tagging SNPs from the SLC6A2 gene and 7 haplotype-tagging SNPs from the SLC6A4 gene were genotyped in 1,125 individuals from several races (EA, AA, Hispanic, Asian, and other) using TaqMan genotyping assays (Life Technologies, Foster City, CA) according to the manufacturer's recommendations.
After calling and cleaning of genotype data using Sequence Detection Systems version 2.4.1, 29 SNPs and 1,021 women were available for the association test. Haploview was used for SNP descriptive statistics. 26 The association test was performed separately for EA (396 cases and 392 controls) and AA (125 cases and 81 controls) women. Other ethnicities were not included in the analysis because of small sample size.
Proc Casecontrol was used to test the association between HF status and SNP, using an additive genetic model with 10,000 permutations to calculate empirical P values. Proc Logistic was used to calculate the odds ratio (OR) for significant SNPs, adjusted for age, menopause status (premenopausal, perimenopausal), smoking status (current, former, never), and BMI. All statistical analyses were performed using SAS statistical software version 9.2 (SAS Institute, Cary, NC). False discovery rate (FDR) was used to correct for multiple testing. 27 Bioinformatics analyses were performed using several online utilities (including SNAP, 28 SNPinfo, 29 RegulomeDB, 30 and DIANA-microT 3.0 31 ) to examine the predicted functionality of significant SNPs and those that are highly correlated with them. Table 1 shows the basic characteristics of the study participants by HF status separately for EA and AA. Women who experienced HFs were more likely to be older and to be current or former smokers. EA women who experienced HFs had significantly higher BMI than EA women who did not experience HFs. Although there were comparable numbers of women with and without HFs among EA women, the number of AA women who experienced HFs was significantly higher than the number of AA women who did not experience HFs. Table 2 shows the basic statistics for the 29 SNPs used in the analysis. All SNPs were in Hardy-Weinberg equilibrium (P 9 0.001) and had a mean call rate of 98%. Minor allele frequency for most of the SNPs was different between EA and AA women; in several cases, the minor allele was switched between the two races (consistent with publicly available data). Table 3 shows the empirical P values for the association between SNP and HF status separately for EA and AA women. Only two SNPs in the SLC6A4 gene were significantly associated with HF status in EA women after accounting for multiple testing: rs2066713 (P = 0.0009; FDR, 0.02) and rs11080121 (P = 0.0038; FDR, 0.05). The ORs for the minor alleles of these two SNPsVadjusted for age, menopause status (premenopausal, perimenopausal), smoking status (current, former, never), and BMIVshowed that the minor allele A of rs2066713 was a risk factor for HFs (OR, 1.29; 95% CI, 1.03-1.60), whereas the minor allele C of rs11080121 was protective against HFs (OR, 0.75; 95% CI, 0.60-0.94).
RESULTS
Bioinformatics analyses identified 21 SNPs that are highly correlated with rs11080121 (r 2 9 0.8). One of these 21 SNPs (rs1042173; r 2 = 1) is found in the 3 ¶ untranslated region of SLC6A4 and located in the microRNA (miRNA) recognition element of two miRNAs (hsa-miR-142-5p and hsa-miR-590-3p).
The minor allele C of rs1042173 seems to disrupt the first nucleotide of a conserved binding site for hsa-miR-590-3p. Three of these 21 SNPs (rs1906451, rs7224199, and rs4583306) had a Regulome score of 1f (likely to affect binding and linked to gene expression). Another one of these 21 SNPs (rs9303628) had a Regulome score of 2b (likely to affect binding). No evidence of functionality was found for rs2066713 or for any of its highly correlated SNPs.
DISCUSSION
Although the precise mechanism of HFs is not known, one explanation is that, in asymptomatic women, there is a thermoneutral zone (about 0.4-C) within which fluctuations in core body temperature do not trigger compensatory mechanisms such as HFs or sweating. 32 In symptomatic women, the thermoneutral zone may be reduced such that even minor fluctuations in core body temperature reach the limits of the zone and initiate a thermoregulatory response. The narrowing of the zone may be attributable to noradrenaline (also called norepinephrine) activation caused by a lack of estrogen and/or serotonin action. Estrogens enhance the synthesis of serotonin and inhibit the production of noradrenaline. 33<35 Therefore, interventions that increase estrogen and serotonin levels and decrease noradrenaline levels may widen the thermoneutral zone and may therefore be expected to reduce HFs. Indeed, ET and HT are the most efficacious therapies for alleviating HFs, but SSRIs and/or SSRIs/SNRIs have also shown efficacy in preclinical 36 and clinical studies. 6<8 However, response to SSRIs/SNRIs has been heterogeneous (ie, SSRIs or SNRIs reduce the frequency and severity of HFs in some women, but they do not have beneficial effects on other women). We hypothesized that this heterogeneous response may be attributable to SNPs in the serotonin and norepinephrine transporter genes. To the best of our knowledge, this is the first study to test the association between HFs in both EA and AA premenopausal and perimenopausal women and genetic variants in two neurotransmitter transporter genes, SLC6A2 and SLC6A4. SLC6A2 (norepinephrine transporter) and SLC6A4 (serotonin transporter) are both members of the sodium-neurotransmitter symporter family, which transports neurotransmitters from synaptic clefts into presynaptic neurons. Multiple polymorphisms in these genes were repeatedly found to be associated with several psychiatric disorders and their response to different drugs. 24 Our study identified two SNPs within the SLC6A4 gene that are significantly associated with HF status only in EA women. The minor allele C of one of these two SNPs (rs11080121) was found to be protective against HFs (OR, 0.75; 95% CI, 0.61-0.93). SLC6A4_rs11080121 was fully correlated with another SNP (rs1042173) in the 3 ¶ untranslated region of SLC6A4, which was found by bioinformatics analyses to have good evidence for functionality. The minor allele C of rs1042173 seems to disrupt the first nucleotide of a conserved binding site for hsa-miR-590-3p. Disrupting a binding site for miRNA, which usually down-regulates gene expression, 37 could lead to higher expression of SLC6A4, which might look like a contradiction because SSRIs/SNRIs work by inhibiting the production of SLC6A4. However, the higher levels of SLC6A4 will increase the uptake of serotonin from synaptic clefts back into presynaptic neurons, leading to lower levels of serotonin available for transmission. This shortage in serotonin will activate the feedback mechanism that is orchestrated by presynaptic autoreceptors and will trigger the production of more serotonin in presynaptic neurons. 38 The shortage in serotonin will also trigger postsynaptic neurons to compensate by increasing the numbers of postsynaptic serotonin receptors. 39 Therefore, for a woman who has been born with a variant that increases the production of SLC6A4, the autoreceptor feedback mechanism may cause her neurons to release more serotonin, which will protect her from HFs in adulthood, consistent with our results. The autoreceptor feedback mechanism explains the contradiction between the protective effect of SSRIs (which work by inhibiting the production of SLC6A4) and the higher risk for mood disorder and depression (which have been observed in animals and humans harboring the short allele of 5-HTTLPR that reduces SLC6A4 expression). 38<40 Interestingly, hsa-miR-590-3p was previously associated with two different neurological disorders: Alzheimer disease and autism spectrum disorder (ASD). In women with Alzheimer disease, hsa-miR-590-3p has been identified as a possible down-regulator for the heterogeneous nuclear ribonucleoprotein A1 (hnRNP-A1) gene, which plays a role in neurodegenerative disorders. 41 In ASDs, hsa-miR-590-3p has been identified as the most important miRNA to potentially regulate a long list of ASD-associated genes. 42 On the other hand, hsa-miR-142-5p, in combination with another miRNA, was found to be associated with gastric cancer recurrence 43 and was recently strongly correlated with gene expression and methylation level in several cancer types. 44 SLC6A4_rs11080121 was also highly correlated with several other SNPs that were found by bioinformatics analyses to have a high probability of affecting the binding of transcription factors and of dysregulating gene expression. All identified associations warrant replication in another study, and their predicted functionality needs to be tested and confirmed experimentally. The associated SNPs also need to be examined for their association with differential response to SSRIs as HF treatment, especially among EA women, to identify those who will better benefit from this medication and to prescribe a different type of medication for women who might not benefit from SSRIs.
Our study is limited by the small sample size in the AA population, which might explain the lack of significance among them. However, the lack of association might also be a result of actual genetic heterogeneity between EA and AA women. A larger study is needed to clarify if this is the case.
CONCLUSIONS
In light of the current trend for personalized clinical medicine, our ultimate goal is to assist in the design of nonhormone tailored pharmaceutical treatments based on SNP status. The study described above is the first step in this direction. 
